Andrew Eschenbach
Andrew Eschenbach
access among choose clinical commitment decisions design doctors easier effective giving growing health help information label meaningful number optimize practice safety step tools treatments turn
The new label design makes it easier for doctors to get access to important information about drug safety and benefits, and this in turn will help them have more meaningful discussions with their patients. This redesigned label is a big step in our commitment to giving health professionals the tools and information they need to optimize their clinical practice and choose among a growing number of effective treatments to make more personalized prescribing decisions for their patients.
cancer certain clinical ensure healthcare institute national providers rapidly research results treatments wants widely
The National Cancer Institute wants to make certain the results of clinical research are rapidly disseminated to healthcare providers and patients, to ensure life-enhancing cancer treatments are widely available.
clearer cut document fastest fresh growing guidance hazards health help improve introduced produce production providing reduce safety sector
Fresh cut produce is the fastest growing sector of the fresh produce industry. This document should help to improve safety by providing clearer guidance on how to reduce health hazards that are potentially introduced during the production process.
ability academic advantage approaches available barriers biggest clinical conducting early enable enter era face full guidance lab research scientists target testing
One of the biggest barriers research and academic institutions face is the ability to get discoveries made in the lab into clinical testing. The new Exploratory IND guidance emphasizes the flexibility available to researchers when conducting early clinical testing of these cutting-edge treatments. As we enter the era of personalized medicine, these exploratory approaches enable scientists to take full advantage of new technologies to target the development of more individualized therapies.
exposure further guidance lead level minimal reduce risk
This new guidance level will further reduce an already minimal risk from lead exposure in candy.